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Abstract: Treatment options for Clostridium difficile infection (CDI) remain limited despite 
this usually nosocomial infection posing an urgent threat to public health. A major paradox of 
the management of CDI is the use of antimicrobial agents to treat infection, which runs the 
risk of prolonged gut microbiota perturbation and so recurrence of infection. Here, we explore 
alternative CDI treatment and prevention options currently available or in development. Notably, 
strategies that aim to reduce the negative effects of antibiotics on gut microbiota offer the potential 
to alter current antimicrobial stewardship approaches to preventing CDI.
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Introduction
Over the last three decades, our understanding of the pathophysiology, epidemiology, 
diagnosis, and treatment of Clostridium difficile infection (CDI) has grown, notably 
as the incidence and severity of infections have increased dramatically.1 From 1935, 
when first cultured by Hall and O’Toole, until the 1970s, when its role in antibiotic-
associated diarrhea and pseudomembranous colitis was elucidated, the C. difficile 
bacterium was believed to be relatively unimportant in clinical significance.2,3 The 
initiation of antibiotic therapy usually leads to perturbation of the intestinal microbiota. 
Cessation of therapy gradually enables a return to a pretreatment state, a concept called 
colonization resistance or community resilience. However, this resilience is not neces-
sarily complete, and the resultant patient’s intestinal microbiota may remain perturbed 
for months after antibiotic cessation.4–6 C. difficile can exploit the niche created by 
the effects of antibiotics on the intestinal microbiota, either by the expansion of strain 
already present before antimicrobial therapy commenced or following the acquisition 
of a strain while colonization resistance remains perturbed.
The rise to prominence of C. difficile as a cause of infective diarrhea was height-
ened by the emergence of the NAP1/BI/027 strain in the early to mid-2000s and its 
association with more severe CDI.7 The recognition of community-acquired CDI 
has added another new dimension of concern.8 Today C. difficile is widely recognized 
as the leading cause of infective nosocomial diarrhea globally and is associated with 
significant morbidity and mortality.9–11 These facts, coupled with the probability that 
CDI might be substantially underdiagnosed in some settings, serve to support its 
designation by the CDC as an urgent public health threat.12–14
The resident microbiota of the gastrointestinal tract plays a crucial role in protect-
ing against invading pathogenic microorganisms via colonization resistance.15,16 Any 
exposure to an antibiotic is a major risk factor for the development of CDI; enhanced 
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Table 1 therapeutic regimens for cDI
First-line option Second-line option
Nonsevere CDI
Metronidazole (500 mg tID 10 days)* vancomycin (125 mg QID 10 days)**
Fidaxomicin (200 mg BID 10 days)**
Severe CDI
vancomycin 
(125 mg QID 10 days)*
Fidaxomicin (200 mg BID 10 days)**
First recurrence
vancomycin (125 mg QID 10 days)**
Fidaxomicin (200 mg BID 10 days)**
Metronidazole (500 mg tID  
10 days)***
Notes: For information on rates of recurrence for each therapeutic regimen, please 
refer escMID guidelines. *Indicates strong support for recommen dation of use; 
**Indicates moderate support for recommendation of use; ***Indicates marginal 
support for recommendation of use. Data from Debast et al.30
Abbreviations: cDI, Clostridium difficile infection; tID, three times daily; QID, four 
times a day; BID, twice daily.
CDI risk has been shown to persist for up to 3 months 
postexposure.17,18 This is particularly true with clindamycin, 
the penicillins ampicillin or amoxicillin, cephalosporins, and 
fluoroquinolones.19–22 In an effort to minimize exposure to 
these selected classes of drugs, interventions have been made 
to substitute one class (eg, a ureidopenicillin) for another (eg, 
an oxyimino-cephalosporin) in an attempt to reduce rates 
of CDI.20 Additionally, there is evidence that the class of 
drug is not the only parameter to consider when selecting a 
particular agent. Another important determinant of CDI risk 
is the cumulative antibiotic exposure as measured by length 
of therapy and number of different antibiotics used, either 
simultaneously or sequentially.23
As stated in the Infectious Disease Society of America/ 
Society for Healthcare Epidemiology of America (IDSA/
SHEA) guidelines for developing an institutional program 
to enhance antibiotic stewardship, “The primary goal of 
antimicrobial stewardship is to optimize clinical outcomes 
while minimizing unintended consequences of antimicrobial 
use, including toxicity, the selection of pathogenic organisms 
(such as C. difficile), and the emergence of resistance”.24 As 
previously stated, the use of broad-spectrum (workhorse) 
antimicrobials such as penicillins, cephalosporins, and fluo-
roquinolones as empiric agents is associated with subsequent 
CDI development. This concept is sometimes referred to as 
“collateral damage”. Ideally, the use of these higher CDI risk 
antimicrobial classes should be minimized or avoided entirely, 
but this is not always practical. Furthermore, restriction of 
whole antibiotic classes will likely lead to less diversity of 
antimicrobial prescribing, which is associated with increased 
risk of resistance.25,26 Notably, however, the collateral dam-
age caused by antibiotic use may be more serious than the 
original infection. Furthermore, many patients, particularly 
the elderly with multiple comorbidities, are recipients of 
antibiotic polypharmacy, possibly starting in the community 
setting and then continuing after hospitalization.
Should CDI occur, the first step in treatment is the 
discontinuation of all antibiotics, if possible. This is usu-
ally impractical, especially in patients with serious and/or 
multiple comorbidities.27–29 The 2014 European Society of 
Clinical Microbiology and Infectious Diseases (ESCMID) 
guidelines recommend metronidazole as initial therapy for 
mild-to-moderate CDI, with oral vancomycin reserved for 
more severe cases (Table 1).30 However, recently published 
data show that vancomycin was superior to metronidazole 
in achieving clinical success for all patients in a combined 
Phase III database.31 For severe, complicated cases of CDI, 
oral vancomycin, with or without IV metronidazole, plus 
a vancomycin retention enema if ilius is present is recom-
mended (Table 1).
Fidaxomicin was approved by the FDA in 2012 for the treat-
ment of C. difficile-associated diarrhea in adults ($18 years 
of age). Fidaxomicin is a narrow-spectrum agent with 
minimal systemic absorption when administered orally, 
possesses low activity against normal gut microbiota, and is 
active against C. difficile, most strains of staphylococci, and 
enterococci.32,33 Fidaxomicin has been shown to be noninfe-
rior to vancomycin for initial cure in patients with CDI and 
was associated with a lower recurrence rate and superior 
sustained clinical response.34,35 Adverse event rates were 
similar; overall, 5.9% of patients on fidaxomicin and 6.9% 
on vancomycin withdrew from trials as a result of adverse 
events. Fidaxomicin was demonstrated to be superior to van-
comycin in patients with non-NAP1/BI/027 strains.36 In the 
United Kingdom, use of fidaxomicin should be considered 
in patients with severe CDI who are considered at high risk 
of recurrence or not responding to vancomycin therapy. It is 
also the recommended option for patients with a first recur-
rence of CDI (Table 1).37 Use of fidaxomicin, however, has 
remained limited due to its high price, a negative attribute 
further exacerbated by the recent availability of a generic 
version of oral vancomycin in the United States.38
It is important to note that current standards of care for CDI 
(metronidazole, vancomycin, or fidaxomicin) are associated 
with at least 12%–20% levels of recurrence, with further recur-
rences more likely in those who require follow-up treatment.39 
High gut concentrations of conventional CDI therapeutic 
agents can adversely affect the microbiota, leading to second-
ary infections (relapses and reinfections) of CDI and selection 
of other potential pathogens, such as enterococci.40
Our approach to CDI management needs to be multifac-
torial and incorporate improved diagnostics, epidemiology, 
Infection and Drug Resistance 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
335
Role of antibiotic therapy in cDI – is prevention possible?
Table 2 Alternative Clostridium difficile infection preventative and 
therapeutic approaches
Approach Product Development 
stage
Microbiological •  Microbiota supplementation  
(fecal microbiota transplant)
n/a
•  RBX2660 (Rebiotix; an oral  
preparation of live microbes)
Phase II
•  seR109 (seresHealth;  
an orally delivered  
combination of spores)
Phase I/II
•  vP20621 (shire [formerly  
viroPharma]; spores of NtcD  
strain M3)
Phase II
Nonmicrobial 
biological
•  Passive immunization  
(MK3415A [Merck])
Phase III
•  vaccines: 
C. diffense (Sanofi Pasteur) 
PF-06425090 (Pfizer) 
Ic84 (valneva)
 
Phase III 
Phase II 
Phase I
Antibiotic 
inactivation
•  sYN-004 (synthetic Biologics;  
a synthetic class A β-lactamase  
enzyme for use with Iv  
cephalosporins [including  
ceftriaxone] and penicillins)
•  DAv132 (Davolterra; a  
medical device consisting  
of an activated-charcoal- 
based product in an enteric- 
coated pill)
Phase II 
 
 
 
 
Phase I
Note: Adapted from Drug Discovery today, volume 20, Ivarsson Me, Leroux J, 
castagner B, Investigational new treatments for Clostridium difficile infection, Pages 
602–608, copyright 2015, with permission from elsevier.39
Abbreviations: n/a, not available; NtcD, nontoxigenic Clostridium difficile.
infection control, antibiotic stewardship, and prevention and 
treatment options. Currently, there are multiple antimicrobial 
agents (eg, cadazolid [Actelion], surotomycin [Cubist], 
SMT19969 [Summit Corporation], and CR3123 [Crestone]) 
in various stages of development for the treatment of CDI.39,41 
In addition to this traditional CDI management strategy, sev-
eral different approaches to the prevention and treatment of 
CDI that do not utilize antibiotic agents to treat established 
infections are in development (Table 2). Although all differ 
from each other on a mechanistic level, most are grounded 
on the principle of attempting to spare, protect, or repair the 
endogenous gut flora.42
The microbiological supplementation approach, notably 
fecal microbiota transplant and Rebiotix oral preparation 
(Table 2), addresses the high rates of recurrence and particu-
larly the debilitating impact of multiple recurrences follow-
ing treatment with either vancomycin or metronidazole by 
attempting to restore the “normal” gut flora. With the excep-
tion of VP20621, none of the approaches listed are aimed at 
preventing the initial episode of CDI. Additionally, because 
the infective process can still be active and the need for anti-
biotic cover still exists, these strategies are primarily aimed 
at present for the treatment of CDI recurrence. Furthermore, 
the administration of antibiotics could obviate such therapies, 
as this would reinterrupt the gut microbiota.
The nonmicrobial biological approach (Table 2) encom-
passes passive immunization and vaccination and target the 
toxins produced by the C. difficile bacterium. Monoclonal 
antibodies given in addition to either metronidazole or vanco-
mycin were superior to standard treatment alone for the pre-
vention of recurrence in a Phase II study; Phase III studies are 
nearing completion.43 The therapy with this adjuvant antibody 
did not, however, improve the severity of illness, the length of 
hospitalization, or the time to resolution of diarrhea.
There are multiple key issues to be addressed for the 
development of an effective vaccine for CDI, including 
antigen(s) selection, delivery system, patient selection, 
and immunoresponsiveness, particularly in the elderly.44,45 
In addition, the requirement for multiple doses of vaccine 
impacts negatively on the development and success of a 
toxoid vaccine.46 Additionally, current vaccines do not inhibit 
colonization by C. difficile.39
The third approach, antibiotic inactivation (Table 2), 
is targeted at eliminating the collateral damage associated 
with the initial antibiotic exposure, thereby potentially reducing 
the risk of CDI.39 As antibiotics are often necessary, the co- 
administration of an agent such as SYN-004 can inactivate the 
antibiotic in the large intestine, thereby allowing the systemic 
distribution of the active agent but avoiding the damage asso-
ciated with the antibiotic to the intestinal microbiota, thereby 
preventing CDI. As such, the antibiotic inactivation approach is 
a novel strategy that could not only prevent the initial episode 
of CDI but also allow the continued use of broad-spectrum 
penicillins and cephalosporins, which are widely prescribed 
for empiric treatment of serious infections.
Recently, there was a call by Gerding and Johnson for 
“inside the box” and “outside the box” thinking in treating 
CDI.47 “Inside the box” agents include vancomycin, metron-
idazole, fidaxomicin, and the other agents previously listed 
that are to be used to treat CDI. “Outside the box” approaches 
to CDI treatment and prevention include the microbiological, 
nonmicrobiological, and antibiotic inactivation approaches 
discussed earlier. These avoid “the continued suppression of 
normal bacterial microbiota that occurs with antimicrobial 
management”.47
In closing, our understanding of the importance of 
C. difficile has been transformed in the three decades since 
its discovery as a human pathogen; it is now considered to 
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be an urgent public health threat. CDI is closely associated 
with the use of antibiotics. As such, a key negative impact of 
CDI is the ability to continue to safely prescribe particular 
antibiotics, notably penicillins and cephalosporins, which 
have long been considered to be valuable classes for treating 
serious infections. Using an antibiotic inactivation approach 
can both potentially reduce the risk of collateral damage 
and CDI and allow the continued clinical use of valuable 
antibiotics. This approach could provide reassurance that, 
even in patients at increased risk of CDI, antibiotic therapy 
can be initiated and continued to achieve optimal clinical 
outcomes. The development of microbiome-friendly inter-
ventions could also be beneficial in preventing the establish-
ment and selection of other multidrug-resistant organisms 
that exploit the niches created by antibiotic-induced col-
lateral damage.
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